BCLI
BRAINSTORM CELL THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−1.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +16.4%
- EBIT
- +16.4%
- EPS
- +47.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -4.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.7%
- EBIT
- +14.9%
- Net income
- —
- EPS
- —
- Free cash flow
- +23.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026